期刊
JOURNAL OF THE NEUROLOGICAL SCIENCES
卷 274, 期 1-2, 页码 9-12出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2008.07.027
关键词
Regulatory cell; TGF-beta; Antibody; Multiple sclerosis; Autoimmunity
资金
- NIAID NIH HHS [R01 AI043458-10, R01 AI043458] Funding Source: Medline
One of the major goals for the immunotherapy Of autoimmune diseases is the induction of regulatory T cells that mediate immunologic tolerance. Parenteral administration of anti-CD3 monoclonal antibody is an approved therapy for transplantation in humans and is effective in autoimmune diabetes. We have found that oral administration of anti-CD3 monoclonal antibody is biologically active in the gut and suppresses experimental autoimmune encephalomyelitis both prior to disease induction and at the height of disease. Oral anti-CD3 antibody acts by inducing a unique type of regulatory T cell characterized by latency-associated peptide (LAP) on its cell surface that functions in vivo and in vitro via TGF-beta dependent mechanism. Orally delivered antibody would not have side effects including cytokine release syndromes, thus oral anti-CD3 antibody is clinically applicable for chronic therapy. These findings identify a novel and powerful immunologic approach that is widely applicable for the treatment of human autoimmune conditions. (C) 2008 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据